Want to see SLP full AI Analyst Report?
SLP Stock Chart & Stats
$11.43
-$4.39(-14.45%)
At close: 4:00 PM EST
$11.43
-$4.39(-14.45%)
Day’s Range― - ―
52-Week Range$11.09 - $21.01
Previous CloseN/A
Volume738.72K
Average Volume (3M)376.87K
Market Cap
$371.58M
Enterprise Value$343.53M
Total Cash (Recent Filing)$41.84M
Total Debt (Recent Filing)$508.00K
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Jul 09, 2026EPS Estimate
0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.12
Shares Outstanding20,205,482
10 Day Avg. Volume586,720
30 Day Avg. Volume376,869
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.28
Price to Sales (P/S)3.60
P/FCF Ratio16.36
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue4.27
Enterprise Value/Gross Profit6.88
Enterprise Value/Ebitda19.85
Forecast
1Y Price Target
$17.67Price Target Upside54.56% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)0.87
Revenue Forecast (FY)$81.71M
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation & Very Low LeverageRobust operating cash flow and free cash flow plus virtually no debt create durable financial flexibility. This funds R&D, services delivery, and potential M&A without refinancing risk, supports near-term execution, and cushions the business through cyclical biotech spending variations.
High Software Margins And Recurring Revenue MixVery high software gross margins and a subscription/renewal model underpin scalable, high-margin recurring revenue. A sizable installed base with meaningful ARPC and cross-sell history supports durable revenue per account and margin sustainability as services complement software sales.
Strategic Take‑private + Platform CombinationThe pending Altaris acquisition and planned combination with Chemical Computing Group is a structural change that could accelerate integrated, cloud‑AI product development, expand addressable market and create scale advantages, supporting longer‑term subscription conversion and product bundling.
Bears Say
Sharp Deterioration In Reported ProfitabilityA severe swing to large net losses and deeply negative margins materially weakens returns and capital efficiency. Even with strong cash flow, recurring losses increase reliance on non‑operational items or one‑offs being resolved and raise questions about sustainable operating leverage and earnings quality.
Softening Renewal Rates And Concentrated ChurnDeclining renewal rates and churn concentrated in early‑stage and smaller pharma reduce predictability of recurring revenue and weaken lifetime customer value. This makes growth more reliant on new sales and cross‑sell, increasing marketing/service costs and pressuring sustainable margin expansion.
Sustained Higher Effective Tax Rate Weighing On EPSA materially higher projected effective tax rate driven by jurisdictional mix and GILTI reduces net income and cash available for reinvestment. If persistent, this structural tax burden will depress reported EPS growth and constrain retained earnings over multiple years.
Simulations Plus News
SLP FAQ
What was Simulations Plus’s price range in the past 12 months?
Simulations Plus lowest stock price was $11.09 and its highest was $21.01 in the past 12 months.
What is Simulations Plus’s market cap?
Simulations Plus’s market cap is $371.58M.
When is Simulations Plus’s upcoming earnings report date?
Simulations Plus’s upcoming earnings report date is Jul 09, 2026 which is in 5 days.
How were Simulations Plus’s earnings last quarter?
Simulations Plus released its earnings results on Apr 09, 2026. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.03.
Is Simulations Plus overvalued?
According to Wall Street analysts Simulations Plus’s price is currently Undervalued.
Does Simulations Plus pay dividends?
Simulations Plus pays a Quarterly dividend of $0.06 which represents an annual dividend yield of N/A. See more information on Simulations Plus dividends here
What is Simulations Plus’s EPS estimate?
Simulations Plus’s EPS estimate is 0.23.
How many shares outstanding does Simulations Plus have?
Simulations Plus has 20,205,482 shares outstanding.
What happened to Simulations Plus’s price movement after its last earnings report?
Simulations Plus reported an EPS of $0.35 in its last earnings report, beating expectations of $0.32. Following the earnings report the stock price went up 0.385%.
Which hedge fund is a major shareholder of Simulations Plus?
Currently, no hedge funds are holding shares in SLP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Simulations Plus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$17.67 (54.56% Upside)
$17.67 (54.56% Upside)
Blogger Sentiment
Neutral
SLP Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 309.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.16%
12-Months-Change
Fundamentals
Return on Equity
-49.30%
Trailing 12-Months
Asset Growth
-27.28%
Trailing 12-Months
Company Description
Simulations Plus
Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 and maintains its headquarters in Lancaster, California.
SLP Company Deck
SLP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a generally positive operational and financial picture: revenue growth (+8% YoY), strong adjusted EBITDA and margin expansion, increased services backlog, high software gross margins, and a solid balance sheet with $41.8M in cash and no debt. Strategic partnerships with three large pharma customers and continued AI integration represent meaningful long-term upside. Offsetting these positives were a pronounced decline in clinical operations revenue (–54%), lower trailing renewal rates (87% TTM), a materially higher effective tax rate (now 23–25%) reducing EPS, reduced other income, and management's deliberately conservative guidance due to macro fragility and limited near-term AI monetization. Overall, the encouraging growth, margins, cash position and strategic progress materially outweigh the notable but contained operational and tax headwinds.View all SLP earnings summariesSLP Stock 12 Month Forecast
Average Price Target
$17.67
▲(54.56% Upside)
Technical Analysis
Ownership Overview
17.21% Insiders
14.82% Mutual Funds
32.12% Other Institutional Investors
25.84% Public Companies and
Individual Investors